Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer and weight-loss therapy.

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their prescribed obesity medication, according to findings published in Obesity.

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

About SURMOUNT-1 SURMOUNT-1 (NCT04184622) was a multi-center, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to ...

Semaglutide activates receptors of the hormone GLP-1 (glucagon-like peptide-1) while tirzepatide activates that hormone as well as a similar one called GIP (glucose-dependent insulinotropic ...

DelveInsight’s Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline ...